Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. RepliCel Life Sciences Inc.
  6. Company
    REPCF   CA76027P4006

REPLICEL LIFE SCIENCES INC.

(REPCF)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
Business Summary
Logo RepliCel Life Sciences Inc.
RepliCel Life Sciences Inc. is a regenerative medicine company. It is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.
Sales per Business
20192020Delta
Cell Replication Technology0.2571.4%0.35100% +40.03%
CAD in Million
Sales per region
20192020Delta
Canada0.2571.4%0.35100% +40.03%
CAD in Million
Managers
Name Title Age Since
Robert Lee Buckler President, CEO, Secretary & Director 55 -
Simon S. Ma Chief Financial Officer & Finance Director 57 2018
Rolf Hoffmann, Dr. Chief Medical Officer 60 2016
Kevin McElwee, Dr. Chief Scientific Officer 51 2010
Peter Lewis Independent Director 66 2011
Members of the board
Name Title Age Since
David M. Hall Chairman 68 2016
Peter Lewis Independent Director 66 2011
Robert Lee Buckler President, CEO, Secretary & Director 55 -
Andrew Schutte Director 32 2018
Peter Lowry Director 58 2018
Gary Boddington Director 53 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,161,601 18,042,665 49.9% 0 0.0% 49.9%
Shareholders
NameEquities%
YOFOTO (China) Health Industry Co., Ltd. 5,357,900 14.5%
MainPointe Pharmaceuticals LLC 3,986,687 10.8%
Andrew Schutte 3,977,301 10.7%
Jamie Mackay 2,235,833 6.03%
Peter Lowry 798,582 2.16%
Kevin McElwee 658,412 1.78%
Rolf Hoffmann 489,572 1.32%
David M. Hall 435,910 1.18%
BBVA Asset Management SA SGIIC 328,647 0.89%
Peter Lewis 212,198 0.57%
Company contact information
RepliCel Life Sciences, Inc.
570 Granville Street
Suite 900
Vancouver, BC V6C 3P1

Phone : +1.604.248.8730
Web : http://www.replicel.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of RepliCel Life Sciences Inc.
Sector Bio Therapeutic Drugs